Quoin Pharmaceuticals Ltd. — Form 8-K
Filed November 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 82/100
What the filing says
Quoin Pharmaceuticals announced a private placement of up to $50.0M gross proceeds ($30.8M upfront + $19.2M from warrant exercises) with healthcare-focused institutional investors, closed August 28, 2026. Simultaneously, the company reported positive interim Phase 2/3 data for QRX003 in Netherton Syndrome: 4 of 6 patients (66.7%) achieved primary endpoint of ≥1-grade IGA improvement (p=0.0087 vs. pre-specified alpha 0.0215); key secondary endpoint also significant (p=0.0070). FDA granted Rare Pediatric Disease and Fast Track designations to QRX003 for Peeling Skin Syndrome; EMA granted Orphan Drug Designation. Company expects to complete 20-patient enrollment by end-2026 and report topline Phase 2/3 data Q2 2027.
Why this rating
For a $5.4M market-cap company, $30.8M upfront cash (569% of market cap) is transformational—extends runway to 2028, funds full QRX003 development. Positive interim efficacy data on lead program substantially de-risks regulatory path. Multiple FDA/EMA designations accelerate approval trajectory. Combined, this materially improves near-term survival and near-term value creation probability.
Tradability signal
NO TRADE
No trade: positive news with only +2.5% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.44% over 4 hrs, n=402). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $3.65 ▼ 2.41% | at our read · unknown $3.74 | +10 min · unknown $3.74 ▲ 0.00% | +30 min · unknown $3.74 ▲ 0.00% | +1 hr · unknown $3.74 ▲ 0.00% | +4 hrs · unknown $3.81 ▲ 1.87% |
The stock had already moved +2.47% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.